iSpecimen Inc. Revenue from Contract with Customer, Excluding Assessed Tax
iSpecimen Inc. (ISPC) reported Revenue from Contract with Customer, Excluding Assessed Tax of $2.66 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2024-11-07
- iSpecimen Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $2.66M, a 4.17% decline year-over-year.
- iSpecimen Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $2.86M, a 76.21% increase year-over-year.
- iSpecimen Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-03-31 was $2.29M, a 22.38% decline year-over-year.
- iSpecimen Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-12-31 was $2.58M, a 13.05% decline year-over-year.
- iSpecimen Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $9.93M, a 4.56% decline from fiscal 2022.
- iSpecimen Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $10.40M, a 6.58% decline from fiscal 2021.
- iSpecimen Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $11.14M, a 36.06% increase from fiscal 2020.
- iSpecimen Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $8.18M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | $2.66M 10-Q · filed 2024-11-07 | $5.53M derived: sum of 2 quarters · filed 2024-11-07 | $7.82M 10-Q · filed 2024-11-07 | $10.39M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $2.86M 10-Q · filed 2024-08-06 | $5.15M 10-Q · filed 2024-08-06 | $7.73M derived: sum of 3 quarters · filed 2024-08-06 | $10.51M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $2.29M 10-Q · filed 2024-05-07 | $4.87M derived: sum of 2 quarters · filed 2024-05-07 | $7.64M derived: sum of 3 quarters · filed 2024-11-07 | $9.27M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $5.35M derived: sum of 2 quarters · filed 2024-11-07 | $6.98M derived: sum of 3 quarters · filed 2024-11-07 | $9.93M 10-K · filed 2024-03-13 |
| 2023-09-30 | $2.78M 10-Q · filed 2024-11-07 | $4.40M derived: sum of 2 quarters · filed 2024-11-07 | $7.35M 10-Q · filed 2024-11-07 | $10.31M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.63M 10-Q · filed 2024-08-06 | $4.58M 10-Q · filed 2024-08-06 | $7.54M derived: sum of 3 quarters · filed 2024-08-06 | $10.12M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $2.95M 10-Q · filed 2024-05-07 | $5.91M derived: sum of 2 quarters · filed 2024-05-07 | $8.50M derived: sum of 3 quarters · filed 2024-05-07 | $10.83M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $5.54M derived: sum of 2 quarters · filed 2024-03-13 | $7.88M derived: sum of 3 quarters · filed 2024-03-13 | $10.40M 10-K · filed 2024-03-13 |
| 2022-09-30 | $2.58M 10-Q · filed 2023-11-02 | $4.92M derived: sum of 2 quarters · filed 2023-11-02 | $7.44M 10-Q · filed 2023-11-02 | $9.99M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $2.34M 10-Q · filed 2023-08-02 | $4.86M 10-Q · filed 2023-08-02 | $7.41M derived: sum of 3 quarters · filed 2023-08-02 | $10.12M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $2.52M 10-Q · filed 2023-05-04 | $5.07M derived: sum of 2 quarters · filed 2023-05-04 | $7.79M derived: sum of 3 quarters · filed 2023-05-04 | $10.69M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $2.55M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $5.27M derived: sum of 2 quarters · filed 2023-03-30 | $8.17M derived: sum of 3 quarters · filed 2023-03-30 | $11.14M 10-K/A · filed 2023-03-30 |
| 2021-09-30 | $2.72M 10-Q · filed 2022-11-08 | $5.62M derived: sum of 2 quarters · filed 2022-11-08 | $8.59M 10-Q · filed 2022-11-08 | $11.30M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $2.90M 10-Q · filed 2022-08-04 | $5.87M 10-Q · filed 2022-08-04 | $8.59M derived: sum of 3 quarters · filed 2022-08-04 | $10.84M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $2.96M 10-Q · filed 2022-05-10 | $5.68M derived: sum of 2 quarters · filed 2022-05-10 | $7.93M derived: sum of 3 quarters · filed 2022-05-10 | $9.44M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $4.97M derived: sum of 2 quarters · filed 2022-03-22 | $6.47M derived: sum of 3 quarters · filed 2022-03-22 | $8.18M 10-K · filed 2022-03-22 |
| 2020-09-30 | $2.25M 10-Q · filed 2021-11-04 | $3.75M derived: sum of 2 quarters · filed 2021-11-04 | $5.47M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.50M 10-Q · filed 2021-08-10 | $3.22M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |